CNS-IPI risk categories with corresponding 2 year rates of CNS relapse and proportion of patients in each category from training (DSHNHL) and validation (BCCA) cohorts
| Risk group . | Risk factors . | DSHNHL cohort . | BCCA cohort . | ||
|---|---|---|---|---|---|
| N (%) . | 2-year risk of CNS relapse . | N (%) . | 2-year risk of CNS relapse . | ||
| Low | 0-1 | 1002 (46) | 0.6% | 463 (31) | 0.8% |
| Intermediate | 2-3 | 896 (41) | 3.4% | 694 (46) | 3.9% |
| High* | 4 | 188 (9) | 7.4% | 344 (23) | 12% |
| High | 5 | 62 (3) | 15% | ||
| High | 6 | 13 (1) | 32.5% | ||
| Risk group . | Risk factors . | DSHNHL cohort . | BCCA cohort . | ||
|---|---|---|---|---|---|
| N (%) . | 2-year risk of CNS relapse . | N (%) . | 2-year risk of CNS relapse . | ||
| Low | 0-1 | 1002 (46) | 0.6% | 463 (31) | 0.8% |
| Intermediate | 2-3 | 896 (41) | 3.4% | 694 (46) | 3.9% |
| High* | 4 | 188 (9) | 7.4% | 344 (23) | 12% |
| High | 5 | 62 (3) | 15% | ||
| High | 6 | 13 (1) | 32.5% | ||
One point is scored for any of the following: age >60 years, LDH > normal, ECOG performances status >1, stage III/IV disease, extranodal involvement ≥2 sites, kidney and/or adrenal involvement.
BCCA, British Colombia Cancer Agency.
High risk group (4-6 factors) overall 2-year risk of CNS relapse of 10.2% in DSHNHL cohort